Cosentyx (also known by its generic name secukinumab) was approved by the FDA in January 2015 for the treatment of moderate-to-severe plaque psoriasis in adults. In January 2016, the FDA also approved Cosentyx to treat adults with active psoriatic arthritis.
For patients with plaque psoriasis, Cosentyx is administered by injection under the skin at weeks 0, 1, 2, 3, and 4 and then every 4 weeks. Health care providers may recommend a different dosing schedule for patients with psoriatic arthritis.
To learn more, please visit the Cosentyx website.